Literature DB >> 23901239

Prediction of the severity of acute pancreatitis on admission by urinary trypsinogen activation peptide: a meta-analysis.

Wei Huang1, Kiran Altaf, Tao Jin, Jun-Jie Xiong, Li Wen, Muhammad A Javed, Marianne Johnstone, Ping Xue, Christopher M Halloran, Qing Xia.   

Abstract

AIM: To undertake a meta-analysis on the value of urinary trypsinogen activation peptide (uTAP) in predicting severity of acute pancreatitis on admission.
METHODS: Major databases including Medline, Embase, Science Citation Index Expanded and the Cochrane Central Register of Controlled Trials in the Cochrane Library were searched to identify all relevant studies from January 1990 to January 2013. Pooled sensitivity, specificity and the diagnostic odds ratios (DORs) with 95%CI were calculated for each study and were compared to other systems/biomarkers if mentioned within the same study. Summary receiver-operating curves were conducted and the area under the curve (AUC) was evaluated.
RESULTS: In total, six studies of uTAP with a cut-off value of 35 nmol/L were included in this meta-analysis. Overall, the pooled sensitivity and specificity of uTAP for predicting severity of acute pancreatitis, at time of admission, was 71% and 75%, respectively (AUC = 0.83, DOR = 8.67, 95%CI: 3.70-20.33). When uTAP was compared with plasma C-reactive protein, the pooled sensitivity, specificity, AUC and DOR were 0.64 vs 0.67, 0.77 vs 0.75, 0.82 vs 0.79 and 6.27 vs 6.32, respectively. Similarly, the pooled sensitivity, specificity, AUC and DOR of uTAP vs Acute Physiology and Chronic Health Evaluation II within the first 48 h of admission were found to be 0.64 vs 0.69, 0.77 vs 0.61, 0.82 vs 0.73 and 6.27 vs 4.61, respectively.
CONCLUSION: uTAP has the potential to act as a stratification marker on admission for differentiating disease severity of acute pancreatitis.

Entities:  

Keywords:  Acute Physiology and Chronic Health Evaluation II score; Acute pancreatitis; C-reactive protein; Meta-analysis; Urinary trypsinogen activation peptide

Mesh:

Substances:

Year:  2013        PMID: 23901239      PMCID: PMC3725388          DOI: 10.3748/wjg.v19.i28.4607

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  44 in total

1.  Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study.

Authors:  J P Neoptolemos; E A Kemppainen; J M Mayer; J M Fitzpatrick; M G Raraty; J Slavin; H G Beger; A J Hietaranta; P A Puolakkainen
Journal:  Lancet       Date:  2000-06-03       Impact factor: 79.321

Review 2.  Trypsin activation peptide (TAP) in acute pancreatitis: from pathophysiology to clinical usefulness.

Authors:  J L Frossard
Journal:  JOP       Date:  2001-03

3.  Plasma trypsinogen activation peptide in patients with acute pancreatitis.

Authors:  E Kemppainen; J Mayer; P Puolakkainen; M Raraty; J Slavin; J P Neoptolemos
Journal:  Br J Surg       Date:  2001-05       Impact factor: 6.939

Review 4.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 5.  Role of activation peptides from pancreatic proenzymes in the diagnosis and prognosis of acute pancreatitis.

Authors:  Anders Borgström; Stefan Appelros; Christophe A Müller; Waldemar Uhl; Markus W Büchler
Journal:  Surgery       Date:  2002-02       Impact factor: 3.982

6.  Trypsinogen-2 and trypsinogen activation peptide (TAP) in urine of patients with acute pancreatitis.

Authors:  Marko Lempinen; Ulf-Håkan Stenman; Patrik Finne; Pauli Puolakkainen; Reijo Haapiainen; Esko Kemppainen
Journal:  J Surg Res       Date:  2003-05-15       Impact factor: 2.192

Review 7.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  BMJ       Date:  2003-01-04

8.  Sequential changes in pancreatic markers in acute pancreatitis.

Authors:  M Lempinen; U H Stenman; P Puolakkainen; A Hietaranta; R Haapiainen; E Kemppainen
Journal:  Scand J Gastroenterol       Date:  2003-06       Impact factor: 2.423

9.  Early prediction of severe acute pancreatitis by urinary trypsinogen activation peptide.

Authors:  Zhi-Su Liu; Cong-Qing Jiang; Qun Qian; Quan Sun; Li-Fang Fan; Zhong-Li Ai
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2002-05

10.  Urinary trypsinogen activation peptide is more accurate than hematocrit in determining severity in patients with acute pancreatitis: a prospective study.

Authors:  Zia Khan; Jane Vlodov; Joel Horovitz; Rose Mary Jose; K Iswara; Joseph Smotkin; Alphonso Brown; Scott Tenner
Journal:  Am J Gastroenterol       Date:  2002-08       Impact factor: 10.864

View more
  3 in total

1.  Comparison of contrast-enhanced CT with diffusion -weighted MRI in the Evaluation of patients with acute biliary pancreatitis.

Authors:  Mehmet İlhan; Muhammet Üçüncü; Ali Fuat Kaan Gök; Gizem Öner; Elidor Agolli; Bahar Canbay; Barış Bakır; Recep Güloğlu; Cemalettin Ertekin
Journal:  Turk J Surg       Date:  2017-09-01

2.  Plasma cytokines can help to identify the development of severe acute pancreatitis on admission.

Authors:  Li-Hui Deng; Cheng Hu; Wen-Hao Cai; Wei-Wei Chen; Xiao-Xin Zhang; Na Shi; Wei Huang; Yun Ma; Tao Jin; Zi-Qi Lin; Kun Jiang; Jia Guo; Xiao-Nan Yang; Qing Xia
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 3.  Role of Biomarkers in Diagnosis and Prognostic Evaluation of Acute Pancreatitis.

Authors:  Susanta Meher; Tushar Subhadarshan Mishra; Prakash Kumar Sasmal; Satyajit Rath; Rakesh Sharma; Bikram Rout; Manoj Kumar Sahu
Journal:  J Biomark       Date:  2015-08-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.